

26. (NEW) The composition of claim 25 wherein the  $F(ab')_2$  is bispecific.

27. (NEW) The composition of claim 25 wherein the  $F(ab')_2$  is monospecific.

28. (NEW) The composition of claim 25 wherein each Fab' of the  $F(ab')_2$  has only one hinge region cysteine.

29. (NEW) The composition of claim 28 wherein each Fab' comprises the C-terminal amino acid sequence Cys Ala Ala.

#### REMARKS

The claims have been replaced by claims 25-29 herein. Specification basis for claims 25-29 can be found at least as follows:

Claim 25 - claim 21 (and claim 21 of the priority application); and page 9, lines 1-8

Claims 26 & 27 - page 15, lines 30-33

Claim 28 - page 6, lines 24-31

Claim 29 - claim 11

In that the amendments do not introduce new matter, their entry is respectfully requested.

Respectfully submitted,

GENENTECH, INC.

By:

Wendy M. Lee

Reg. No. 40,378.

Date: November 15, 2000

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-1994

Fax: (650) 952-9881

00577 0404T 250

A2  
concl.